ShadowGraph
Start free trial
SEC filings · customer concentration

Who depends on AmerisourceBergen

2 listed suppliers report AmerisourceBergen as a customer worth 10% or more of their revenue, led by ADC Therapeutics at 39%.

0major customers now
—of revenue from them
2listed suppliers depending on it
2011–2026years covered
Free

Get an email when AmerisourceBergen's customer concentration changes

When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.

We only use your address for this watch. Double opt-in, see our privacy notice.

Suppliers that depend on AmerisourceBergen

Listed companies whose annual report names AmerisourceBergen as a customer worth 10% or more of their revenue. If AmerisourceBergen cuts orders or switches supplier, these are the companies that feel it.

SupplierIts revenue from this companyChange vs prior yearHistoryLatest filing
ADC TherapeuticsADCT39%from 35%FY 2022: 34%FY 2023: 38%FY 2024: 35%FY 2025: 39%4 yearsFY 2025 · filed 10 Mar 2026
ViatrisVTRS11%from 12%FY 2019: 9%FY 2020: 10%FY 2021: 9%FY 2022: 10%FY 2023: 10%FY 2024: 12%FY 2025: 11%7 yearsFY 2025 · filed 26 Feb 2026

Formerly disclosed

SupplierIts revenue from this companyChange vs prior yearHistoryLatest filing
Coherus OncologyCHRS38%last FY 2024FY 2019: 33%FY 2020: 37%FY 2021: 39%FY 2022: 44%FY 2023: 43%FY 2024: 38%6 yearsFY 2024 · filed 17 Mar 2025
Amphastar PharmaceuticalsAMPH23%last FY 2022FY 2012: 14%FY 2013: 15%FY 2014: 15%FY 2015: 17%FY 2016: 21%FY 2017: 28%FY 2018: 27%FY 2019: 24%FY 2020: 23%FY 2021: 24%FY 2022: 23%11 yearsFY 2022 · filed 1 Mar 2023
ArdelyxARDX21%last FY 2023FY 2022: 27%FY 2023: 21%2 yearsFY 2023 · filed 22 Feb 2024
Gilead SciencesGILD18%last FY 2022FY 2016: 18%FY 2017: 20%FY 2018: 20%FY 2019: 21%FY 2020: 27%FY 2021: 23%FY 2022: 18%7 yearsFY 2022 · filed 22 Feb 2023
Bausch Health CompaniesBHC18%last FY 2022FY 2011: 10%FY 2012: 8%FY 2013: 7%FY 2014: 10%FY 2015: 14%FY 2016: 13%FY 2017: 15%FY 2018: 18%FY 2019: 16%FY 2020: 17%FY 2021: 18%FY 2022: 18%12 yearsFY 2022 · filed 23 Feb 2023
ExelixisEXEL17%last FY 2023FY 2017: 8%FY 2018: 9%FY 2020: 11%FY 2021: 14%FY 2022: 18%FY 2023: 17%7 yearsFY 2023 · filed 6 Feb 2024
Akebia TherapeuticsAKBA15%last FY 2022FY 2019: 10%FY 2020: 12%FY 2021: 16%FY 2022: 15%4 yearsFY 2022 · filed 10 Mar 2023
AlkermesALKS12%last FY 2023FY 2020: 10%FY 2021: 11%FY 2022: 14%FY 2023: 12%4 yearsFY 2023 · filed 21 Feb 2024
PfizerPFE5%last FY 2022FY 2018: 8%FY 2019: 11%FY 2020: 14%FY 2021: 7%FY 2022: 5%5 yearsFY 2022 · filed 23 Feb 2023

About this data

US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.

All companies · Latest dependency shifts · Bulk data and API